Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®

About this update from Cipher Pharmaceuticals Inc.

MISSISSAUGA, ON, July 6, 2026 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ("pCPA"), resulting in a Letter of Intent ("LOI") for Epuris® (isotretinoin). Epuris® is an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne con globate, and recalcitrant acne in patients 12 years of age and older. The execution of this LOI represents a critical milestone toward securing expanded public reimbursement and enhancing patient access to Epuris® across Canada. The pCPA is an alliance of Canada's provincial, territorial, and federal public drug plans that conducts joint negotiations to achieve greater value for publicly funded drug programs. Securing an LOI through the pCPA is a critical milestone, as it is a prerequisite under the standard pCPA brand process for individual provinces and territories to list Epuris® on their respective public drug formularies under the negotiated terms; each jurisdiction nevertheless retains the final decision on whether and when to add the product and may impose additional conditions. Following this achievement, Cipher will collaborate with federal, provincial, and territorial public drug plans to finalize Product Listing Agreements ("PLA") to ensure timely access for eligible Canadian patients. "This agreement with the pCPA marks a major milestone in our commercial strategy, establishing a framework for public drug plan coverage and significantly expanding Epuris® access for Canadians navigating severe acne," said Craig Mull, Interim CEO of Cipher. "Epuris® is now positioned to compete equitably across the isotretinoin market, effectively opening treatment paths to a broader patient demographic. We look forward to finalizing federal, provincial and territorial agreements swiftly. Overcoming historical regional access barriers establishes a strong foundation for the next phase of growth for Epuris®." About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and curr...

View stock analysis, news, and events for Cipher Pharmaceuticals Inc.